Lakefront Biotherapeutics (LKFT) Cash from Operations Growth (1y) (2017 - 2026)
Lakefront Biotherapeutics (LKFT) Cash from Operations Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 158.60% |
| 10 | Lakefront Biotherapeutics | 1.85 Bn | -1.54 Bn | 1.91 Mn | -120.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -120.09% |
| Dec 31, 2025 | 21.63% |
| Mar 31, 2025 | 68.09% |
| Dec 31, 2024 | 3.52% |
| Mar 31, 2024 | -38.74% |
| Dec 31, 2023 | 43.95% |
| Mar 31, 2023 | -56.68% |
| Jun 30, 2020 | -97.49% |
| Mar 31, 2020 | 3.73% |
| Dec 31, 2019 | -137.74% |
| Sep 30, 2019 | 69,924.18% |
| Jun 30, 2019 | -8.11% |
| Mar 31, 2019 | -41.17% |
| Dec 31, 2018 | -65.94% |
| Sep 30, 2018 | -100.01% |
| Jun 30, 2018 | 99.90% |
| Mar 31, 2018 | -75.60% |
| Jun 30, 2017 | -245,162.53% |
| Mar 31, 2017 | -109.23% |